pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Immunology · news · pharmadog
← back to Immunology
News mentioning Immunology
280
stories
Sep 28, 26
‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the future
fiercebiotech
Sep 28, 26
Tolerance continues thymus-focused deals with $560M pact for Tanabe's clinical-stage IL-33 drug
fiercebiotech
Sep 28, 26
Opinion: AI is eroding the barriers that kept biological weapons rare
stat
Sep 28, 26
STAT+: Once described as obesity medicines for ‘patients,’ GLP-1s are increasingly lifestyle drugs for ‘customers’
stat
Sep 28, 26
6 immunology targets to sustain a mammoth I&I market
biospace
Sep 25, 26
STAT+: Lilly wins approval for once-weekly insulin shot
stat
Sep 25, 26
Nektar prevails in legal battle with Lilly over broken rezpeg partnership
biospace
Sep 25, 26
ADARx raises $446M in biotech’s third largest IPO of 2026, City files to go public
biospace
Sep 25, 26
Roche's Genentech inks $1.5B bispecific pact with fast-rising Earendil
fiercebiotech
Sep 24, 26
STAT+: FDA commissioner nominee Heidi Overton keeps opinions to herself in Senate hearing
stat
Sep 24, 26
The FDA’s Overton era, and dispatches from Shanghai
stat
Sep 24, 26
Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability data
biospace
Sep 24, 26
STAT+: Why Gilead can’t stop talking about its ambitions in immunology
stat
Sep 23, 26
Immunovant ditches lupus for multi-hyphenate inflammatory drug after mid-stage miss
biospace
Sep 23, 26
Roche’s phase 3 win tees up fight with Novartis for blockbuster kidney disease market
fiercebiotech
Sep 22, 26
Amgen reports a Phase 3 win with Sjögren’s drug candidate
biopharma dive
Sep 22, 26
Celldex sinks as safety concerns cloud immune drug results
biopharma dive
Sep 22, 26
Lilly presents early data supporting GLP-1/GIP candidate's potential in depression, alcohol use disorder
biospace
Sep 22, 26
2026 IPO blitz continues with 4 new biotech filings
biospace
Sep 21, 26
Cue Biopharma's potential Xolair challenger passes Phase 2 chronic hives trial
endpoints
Sep 20, 26
STAT+: Radiopharma companies merge after one receives surprise FDA rejection
stat
Sep 18, 26
China plans to transform biotech sector into $522B powerhouse by 2030
biospace
Sep 18, 26
STAT+: Roche expands its Boston footprint with new research center
stat
Sep 17, 26
STAT+: FDA approves a new gene therapy for Sanfilippo syndrome, an ultra-rare disease
stat
Sep 17, 26
Two more biotechs, Marea and North Immunology, do reverse mergers
endpoints
Sep 17, 26
Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
fiercebiotech
Sep 17, 26
North Immunology joins biotech reverse merger boom with Aethlon deal
biopharma dive
Sep 17, 26
STAT+: New startup to test psychedelic-like drug against Parkinson’s symptom
stat
Sep 17, 26
Roche bets up to $1B to advance next-gen bispecifics with Dualitas
biospace
Sep 17, 26
STAT+: A Sellas immunotherapy study, long delayed, will end in failure
stat
← prev
page 5 of 10
next →